Introduction
Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia in western societies. It has attracted much basic and clinical interest. Despite recent advances in our understanding of the genetics, biology and clinical behavior of CLL, there is still no established cure for the disease and its progression and outcome are highly unpredictable. [1] [2] [3] The diagnosis of 'true' CLL has become very accurate. The most important methods for making a distinction between CLL and other chronic lymphoid leukemias are: (1) cell morphology; 4 (2) immunophenotyping; 5 (3) histology; 6 and (4) chromosome analyses. 7 Using some of these tools, CLL can be subdivided in several categories as regards the cell biology and clinical behavior of the disease. Importantly, distinct disease entities may be marked by chromosomal aberrations or by gene expression anomalies. The former include 11q
We show here that the expression of several structurally and functionally distinct membrane antigens bears statistically highly significant intercorrelations, while some others are stringently mutually exclusive. Furthermore, new associations of chromosome aberrations 11q deletion, 13q deletion and trisomy 12 with exceptional membrane antigen expression will be described.
Materials and methods

Patients and samples
Clinical specimens were obtained after informed consent from 35 consecutive CLL patients referred to the CLL outpatient clinic at Tampere University Hospital, Finland. The inclusion criterion was a blood lymphocyte count 30 × 10 9 /l or more. Clinical and hematological data of 35 CLL patients is illustrated in Table 1 . Diagnosis and staging were based on standard clinical, morphological and immunophenotyping criteria (Table 1 ). In accordance with the B cell phenotype and a commonly used immunological CLL classification, 10 all patients had a CD19 +
/CD5
+ /CD23 + immunophenotype. Typical CLL, CLL/mix or CLL/PL morphology could be assigned to all patients. 4 Most patients showed chromosomal aberrations ( Table 1) . None of these aberrations indicated chronic lymphoid leukemias other than typical CLL. Peripheral blood leukemic cells were isolated using traditional methods as described. 11, 12 The proportion of monocytes plus polyclonal T-and B-lymphocytes was 1-13%, indicating that 87-99% of the isolated cells represented the leukemic population (for details of the immunophenotyping, see below).
Immunophenotyping
Immunophenotyping was performed by flow cytometry (FACSCalibur, Becton Dickinson Immunocytometry systems, San Jose, CA, USA) using commercial mouse monoclonal antibodies and respective immunoglobulin isotype controls (Table 2) . Staining was performed according to the suppliers' instructions. For cell surface immunoglobulin staining, the cells were first incubated in PBS (pH 7.4) at 37°C for 30 min to remove heterophilic antibodies. The buffers used in all the steps did not contain serum.
The forward scatter channel was checked prior to every analysis using unlabeled calibration particles (SPHERO calibration particles, blank 6.5-8 m, Pharmingen, San Diego, CA, USA). Instrument linearity was checked using commercial standard reagents (Immuno-Brite Standards Kit; Coulter, Hialeah, FL, USA) prior to study. Fluorescence compensations were set prior to every analysis using calibrate beads (caliBRITE; Becton Dickinson) and FACSComp software (Becton Dickinson). Instrument calibration was additionally checked using Immunobrite level II standard beads (Coulter). On the basis of the data thus obtained, the interassay variability in this study was 6.5% for FL1 channel and 7.6% for FL2 channel.
Leukemia
The percentages of cells were calculated on the basis of data obtained from two-color immunofluorescence dot blots. Analyses were carried out using CellQUEST Software (Becton Dickinson). Quadrant markers were set relative to negative immunoglobulin isotype controls in a such way that 99% (99.05 ± 0.04) of the cells labeled with the control antibodies were located in the left lower quadrant. When estimating the reactivity of known T cell antigens on the surface of malignant B cells, the proportion of CD2 cells was taken into account. Furthermore, an aberrant expression of T cell antigens CD4 and CD8 in B cells was investigated. As only one case with aberrant CD8 expression was found (patient No. 30 with 32% of CD8-positive B cells), these antigens were not taken into account in cluster analysis. The intensity of antigen expression in the cell membrane was analyzed in a histogram data dis-Leukemia Table 2 Monoclonal antibodies used The intensity of mIgD and mIgM expression in the cell membrane was estimated in a histogram data display, selecting the log scale in the fluorescence axis and arithmetic statistics. The criteria were as follows: weak expression (+/−) when the mean fluorescence value was within the first logarithmic percentile (ie Ͻ10); moderate (+), when the peak was within the second percentile (10-100), and strong (++) or very strong (+++) when the peak was within the third percentile (100-1000) or more (Ͼ1000).
Antigen and Label
Isotype Clone source a CD2 (B) FITC ␥ 2a leu-5b CD4/CD8 (B) FITC/PE ␥ 1 /␥ 2a leu-3a/leu-2a CD20 (B) FITC ␥ 1 leu16 CD45RA (B) FITC ␥ 1 leu-18 CD45RO (B) PE ␥ 2a leu-45RO CD122 (B) PE ␥ 1 anti-IL-2R-p75 CD19 (B) PE ␥ 1 SJ25C1 CD5 (B) FITC ␥ 2a Leu-1 CD23 (B) PE ␥ 1 Leu-20 FMC7 (I) FITC FMC7 CD22 (B) FITC ␥ 2b Leu-14 CD34 (B) PE ␥ 1 8G12 CD38 (B) PE ␥ 1 Leu-17 CD10 (B) FITC ␥ 2a Anti-CALLA CD124 (I) PE ␥ 1 S4-56C9 CD126 (I) PE ␥ 1 M91 CD11c (D) FITC ␥ 1 KB90 CD14 (D) FITC ␥ 2a TUK4 CD21 (D) FITC ␥ 1 1F8 CD79b (D) FITC ␥ 1 SN8 mIgG (P) FITC ␥ 1 G18-145 mIgD (P) FITC ␥ 2a IA6-2 mIgM (P) PE ␥ 1 G20-127 CD95 (P) FITC ␥ 1 DX2 CD40 (P) FITC ␥ 1 5C3 CD27 (P) FITC ␥ 1 M-T271 CD130(P) PE ␥ 1 VC041 CD25 (B) FITC ␥ 1 Anti-IL-2R CD154 (B) PE ␥ 1 Anti-gp39 CD80 (B) PE ␥ 1 Anti-B7 CD45/CD14 (B) FITC/PE ␥ 1 /␥ 2b Anti-Hle-1/Leu- 3M / (B) FITC/PE ␥ 1 /␥ 1 TB28-2/1-155
Statistical treatment
Comparison of two mean values was performed by using Mann-Whitney U-test and more than two means by using Kruskal-Wallis test (ANOVA). Correlations were calculated using Spearman's rank order correlation test. These statistical calculations were carried out using Statistica software (Win 5.1F; StatSoft Inc, Tulsa, OK, USA).
Two-way joining cluster analysis was based on joining or tree clustering methods which makes use of dissimilarities or distance between the objects when forming the clusters. In order to fit the program, the percent of positive cells values were divided by 25. After log2 transformation of these data, hierarchical clustering was applied to both axes using average linkage clustering, as implemented in the program Cluster 2.11 (M Eisen; http://rana.lbl.gov/EisenSoftware.htm). 13 The results were analyzed with Tree View 1.50 (M Eisen; http://rana.lbl.gov/EisenSoftware.htm).
13
Results
Surface antigen expression patterns
Two-way cluster analysis of 31 different membrane antigens of 35 CLL patients is illustrated in Figure 1 . Three different types of clusters could be demonstrated. Antigens CD45, CD5, CD45RA, CD20, CD19, CD23, CD27 and CD40 formed a red cluster of predominantly positive antigens. In contrast, the antigens CD14, CD10, CD154 (CD40 ligand), CD34, mIgG and CD122 (IL-2 receptor, beta chain) were predominantly negative (green). The most variation was observed in the third cluster, containing antigens: CD11c, CD25, CD21, CD79b,CD22, CD124 (IL-4 receptor) (less variation), and CD45RO, mIgM, mIgD, CD38, mIg, mIg, FMC7, CD130 (gp130), CD80 (B7), CD95 (APO-1/Fas) and CD126 (IL-6 receptor) (more variation). In this third cluster, there was a tight correlation between the percentage of positive cells and the geometric mean fluorescence of the corresponding antigens ( Figure 1 and Table 3 ). Although statistically significant (P Ͻ 0.05), poorer correlations were demonstrated for CD40, CD130 and mIgG.
The percentages of positive cells in the red cluster cases approached 90-100%. However, the geometric mean fluorescence (GMF) values were more variable. Hence, GMF values instead of percentages of positive cells were used for further analyses of the association between different patients and the expression of different membrane antigens.
Correlations in the expressions of individual membrane antigens Membrane immunoglobulins:
Light chain expression was easily demonstrable in all cases. Fifty-four percent of the cases were -positive and 46% -positive. 
Other surface membrane antigens:
Pairwise correlations of expression levels of individual antigens were determined by using Spearman's rank order regression analysis. This analysis revealed a statistically significant (P Ͻ 0.05) correlation of expression in 22 individual pairs amongst a total of 19 differ- The cases were selected from the mixed cluster (see Results), when there were at least four cases with у20% positive cells.
ent antigens. Nine pairs with the strongest associations are illustrated in Table 4 . The expression patterns of mIg and mIg were mutually exclusive, as expected (Figure 2) . Interestingly, the same tendency also concerned several other antigen pairs. The clearest examples were CD45RA/CD45RO, CD38/CD80 and CD45RA/CD80 (Figure 2) , and it was also seen in other antigen pairs including CD21/CD80 and CD80/CD126 (results The antigens were selected on the basis of Spearman's rank order regression analysis: all antigen pairs with a highly significant correlation (R у 0.55, n = 35) are included provided that the background geometric mean fluorescence +2 s.d. (95% confidence limit of assay sensitivity; 5 for FITC-and 4 for PE-labeled antibodies) was smaller than the median fluorescence of each antigen to be compared.
Leukemia
not shown, but the patterns can be discerned by referring to Figure 1 ).
Membrane phenotypes in 11q deletion, 13q deletion and trisomy 12
The expression patterns of leukocyte common antigen (CD45) splicing variants CD45RA and CD45RO were strongly affected by the presence of 11q deletion, as well as by trisomy 12: the presence of 11q deletion was associated with significantly suppressed expression of CD45RA and enhanced expression of CD45RO, while the opposite situation was demonstrated in case of trisomy 12 ( Figure 3) . Furthermore, 11q deletion was associated with enhancement of CD20 expression and suppression of CD11c, CD21, CD22 and mIg expression. Trisomy 12 cases, on the other hand, were associated with enhancement of mIg expression, as well as in CD27 expression. 13q deletion was only associated with an increased CD20 expression (Figure 3 ).
Figure 3
Surface membrane antigen expression in 11q-deletion (n = 9) vs non-deletion (n = 26) groups, in trisomy 12 (n = 5) vs non-trisomy groups (n = 30), and in 13q-deletion (n = 21) vs non-deletion groups (n = 14). Mean (point), s.e.m. (column) and 1.96 × s.e.m. (whiskers) is illustrated. The P-values given above each panel were calculated by using Mann-Whitney U test.
Clinical parameters and surface antigen expression
Generally, no marked correlations were noted between the clinical stage (Binet) and expression of CD19, CD22 and CD23. Stage C patients (n = 9) tended to have smaller GMF-CD22 values than Binet A and B patients (n = 26; P = 0.0379, Mann-Whitney U test).
The only surface membrane antigen expression, which significantly changed according to progression status (see Table 1 ), was GMF-CD40 (P = 0.0123, Kruskal-Wallis ANOVA). In particular, stronger expression was noted in fastprogressing cases with chemotherapy (mean 37.1) vs fast-progressing cases not undergoing chemotherapy (mean 23.2, P = 0.0450, Mann-Whitney U test). Expression of none of the membrane antigens correlated significantly to chemotherapy, if patients were dichotomized to two groups, one having received or receiving chemotherapy (n = 8) and the other without previous or ongoing treatment (n = 27).
Antigen expression in CD38 subgroups
It has been shown that CLL can be divided into two functional groups depending on CD38 antigen expression. 8, 13, 14 Furthermore, according to Damle and coworkers, 15 the CD38 positivity (у30%) was suggested to correlate with the clinical outcome of CLL patients. Hence, we analyzed whether CD38 
Discussion
Relatively little is known about the regulation of gene expression in CLL. However, it is well known that CD5, CD19, CD20, CD23, CD40 and CD45, as well as its isoform CD45RA are moderately or strongly expressed in CLL. 16 The results with CD27 have been conflicting. While two previous studies have indicated surface membrane expression of CD27 in most or all CLL cases, 17 ,18 a more recent and larger investigation regarded the expression as negative in CLL. 19 Our results confirm the unequivocal expression of CD27 in typical CLL. The percentage of positive cells ranged from 59 to 98, median 94% (n = 35).
The expressions of most of the comparable antigens were very similar to those reported recently from another laboratory, 19 these being CD11c, CD21, CD22, CD38, CD79b and CD95. This high rate of inter-laboratory concordance reflects the good accuracy and precision of the flow cytometric determinations in these two laboratories. On the other hand, in contrast to two previous studies 19, 20 and in accordance with one study, 21 we found five of 35 cases with more than 50% of CD80-positive cells. Expression of CD154 was negative or low in all cases of the present study. In an earlier report, 22 elevated expression was noted in some CLL cases.
There is very little information concerning the expression of CD124, CD126 or CD130 in CLL. The regulatory functions of CD124 on human normal and CLL B cells are gradually emerging, 23, 24 but very little quantitative data about the expression are available. The moderate but variable expression (37-98% positive cells) of CD124 in CLL, as noted here, deserves further investigation regarding the pathogenesis and minimal residual disease diagnostics of CLL. The expression patterns of CD126 and CD130 have been the subject of only a few studies. In a murine hybridoma model a negative correlation has been noted between IL-6R alpha and IL-6 expression, suggesting negative feedback regulation. 25 Allelic exclusion ensures that functional cells never contain more than one V L J L unit. 26 In other words, the expressions of mIg and mIg are mutually exclusive. In contrast, it is not understood why two splicing variants of the CD45 molecule, ie CD45RA and CD45RO, are differentially expressed in CLL. The heterogeneous expression of these two variants has previously been noted in CLL, but the interpretations of its background have been conflicting. One possibility is that CLL expressing different isoforms may originate from neoplastic expansion of either CD45RO-positive or CD45RO-negative B cells. 27 One study group suggested that CLL cells expressing CD45RO may be more mature cells than those expressing only CD45RA, 28 while another group concluded that the expression of CD45RO in CLL may reflect relative immaturity of these cells. 16 The distinctive association of 11q deletion and trisomy 12 with CD45RA vs CD45RO expression supports the hypothesis that these splicing variants are selected early in the malignant process in CLL. We revealed two other antigen pairs where expression tended to be mutually exclusive: CD80 vs CD38 and CD45RA vs CD80. The present investigation did not reveal any remarkable antigen expression differences in CD38-positive vs CD38-negative cells.
An interesting question from the clinical and cell biological point of view is whether CLL could be subdivided to similar maturational stages as in, for instance, acute lymphoblastic leukemia. If CD27 is accepted as a memory cell marker, as proposed, [28] [29] [30] [31] It has recently been established that genomic aberrations in CLL are important independent predictors of disease progression and survival. 3 Sembries et al 19 have shown that B-CLL cells with or without 11q deletion differentially express functionally relevant cell surface molecules. All of these markers (CD6, CD11a, CD18, CD31, CD35, CD39, CD45, CD48 and CD58) were found at lower levels on cells with 11q deletion than on leukemic cells without this chromosomal aberration. In the present investigation, the inferior expression of CD11c, CD22 and mIg in cases with 11q deletion pointed in the same direction as in the study by Sembries et al. In the current study, the difference reached a statistical significance. In contrast, slightly stronger expression of CD20 was noted here in 11q deletion cases. The most striking novel difference was demonstrated with CD45 isoforms CD45RA and CD45RO. Deletion of 11q was associated with a remarkable attenuation of CD45RA expression, while enhancement of CD45RO expression was noted. Experimental evidence indicates that there may be negatively acting trans-factors that allow the skipping of alternate exons, while the full-length isoform of CD45 represents the default pattern of splicing. 16 It is tempting to think that this kind of differential splicing existed in our cases, where 11q23 deletion has been carefully characterized. [33] [34] [35] Although chromosome 11q22-23 is a gene rich area, we are not aware of any gene which might change the CD45 splicing strategy.
It is of interest that trisomy 12 had the opposite effect on CD45RA/CD45RO expression compared with 11q deletion. The mechanisms of this on CD45 splicing remain to be determined. Similarly, contrasting ratios of mIg expression were noted when 11q deletion and trisomy 12 cases were compared. These observations supported the idea that CLL cases with 11q deletion and those with trisomy 12 may represent independent disease entities. It is interesting to note that 11q23 deletion is also frequent in B cell prolymphocytic leukemia, which ususally has a fast progression. 36 A recent cDNA mRNA profiling analysis from this same patient cohort revealed some interesting gene expression patterns concerning CD14, CD25, CD79b.
37 CD25 mRNA was upregulated in 11q deletion patients. The same tendency, albeit statistically not significant, was observed at the protein level in this study. Another similarity was a higher expression of CD14 in more advanced disease stage, ie Binet A vs B + C (results not shown). Furthermore, CD79b mean expression at the mRNA level was slightly higher in the faster-progressing cases. 37 This was not observed at the protein level in the current work. The explanation may be that the extracellular epitope of CD79b is not necessarily expressed, 38 despite the presence of the pertinent mRNA species. 39 In conclusion, our results revealed a large group of CLL surface membrane antigens with a heterogeneous expression pattern. Some of them are previously unexplored. Many of these antigen expression patterns are case-specific and differ from normal polyclonal B cells. Hence, if determined in the presentation of a case of CLL, they should be very useful in the diagnostics of minimal residual disease after intensive chemotherapy and stem cell transplantation. Moreover, the interrelationships of the expression of seemingly independent surface membrane antigens, as noted here, provide a new basis for more extensive exploration of their role in CLL pathogenesis. Several previously unknown correlations between antigen expression and genomic aberrations were found. It is conceivable that some antigens may have a prognostic role and some could possibly be used as surrogate markers for clonal chromosomal abnormalities. These possibilities remain to be investigated in a considerably larger patient group.
